212 related articles for article (PubMed ID: 22246505)
1. Null alleles of ABCG2 encoding the breast cancer resistance protein define the new blood group system Junior.
Saison C; Helias V; Ballif BA; Peyrard T; Puy H; Miyazaki T; Perrot S; Vayssier-Taussat M; Waldner M; Le Pennec PY; Cartron JP; Arnaud L
Nat Genet; 2012 Jan; 44(2):174-7. PubMed ID: 22246505
[TBL] [Abstract][Full Text] [Related]
2. ABCG2 null alleles define the Jr(a-) blood group phenotype.
Zelinski T; Coghlan G; Liu XQ; Reid ME
Nat Genet; 2012 Jan; 44(2):131-2. PubMed ID: 22246507
[TBL] [Abstract][Full Text] [Related]
3. Molecular analysis of immunized Jr(a-) or Lan- patients and validation of a high-throughput genotyping assay to screen blood donors for Jr(a-) and Lan- phenotypes.
Haer-Wigman L; Ait Soussan A; Ligthart P; de Haas M; van der Schoot CE
Transfusion; 2014 Jul; 54(7):1836-46. PubMed ID: 24456066
[TBL] [Abstract][Full Text] [Related]
4. A review of the JR blood group system.
Castilho L; Reid ME
Immunohematology; 2013; 29(2):63-8. PubMed ID: 24094238
[TBL] [Abstract][Full Text] [Related]
5. A new ABCG2 null allele with a 27-kb deletion including the promoter region causing the Jr(a-) phenotype.
Ogasawara K; Osabe T; Suzuki Y; Tsuneyama H; Isa K; Kawai M; Obara K; Ogiyama Y; Ito S; Uchikawa M; Satake M; Tadokoro K
Transfusion; 2015 Jun; 55(6 Pt 2):1467-71. PubMed ID: 25522810
[TBL] [Abstract][Full Text] [Related]
6. Defining the Jr(a-) phenotype in the Japanese population.
Tanaka M; Kamada I; Takahashi J; Kimura K; Matsukura H; Tani Y
Transfusion; 2014 Feb; 54(2):412-7. PubMed ID: 23713577
[TBL] [Abstract][Full Text] [Related]
7. The JR blood group system (ISBT 032): molecular characterization of three new null alleles.
Hue-Roye K; Lomas-Francis C; Coghlan G; Zelinski T; Reid ME
Transfusion; 2013 Jul; 53(7):1575-9. PubMed ID: 23066723
[TBL] [Abstract][Full Text] [Related]
8. The JR blood group system: identification of alleles that alter expression.
Hue-Roye K; Zelinski T; Cobaugh A; Lomas-Francis C; Miyazaki T; Tani Y; Westhoff CM; Reid ME
Transfusion; 2013 Nov; 53(11):2710-4. PubMed ID: 23438071
[TBL] [Abstract][Full Text] [Related]
9. Two novel ABCG2 alleles resulting in a Jr(a-) phenotype.
Berardi P; Cote J; Vege S; Aeschlimann J; Cserti-Gazdewich C; Westhoff CM
Transfusion; 2017 Nov; 57(11):2811-2812. PubMed ID: 28836283
[No Abstract] [Full Text] [Related]
10. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
11. Ethnic differences in ATP-binding cassette transporter, sub-family G, member 2 (ABCG2/BCRP): genotype combinations and estimated functions.
Sakiyama M; Matsuo H; Takada Y; Nakamura T; Nakayama A; Takada T; Kitajiri S; Wakai K; Suzuki H; Shinomiya N
Drug Metab Pharmacokinet; 2014; 29(6):490-2. PubMed ID: 24869748
[TBL] [Abstract][Full Text] [Related]
12. An update on the JR blood group system.
Castilho L
Immunohematology; 2019 Jun; 35(2):43-44. PubMed ID: 31246485
[TBL] [Abstract][Full Text] [Related]
13. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
14. Increased JNK1 signaling pathway is responsible for ABCG2-mediated multidrug resistance in human colon cancer.
Zhu MM; Tong JL; Xu Q; Nie F; Xu XT; Xiao SD; Ran ZH
PLoS One; 2012; 7(8):e41763. PubMed ID: 22870247
[TBL] [Abstract][Full Text] [Related]
15. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
16. Multidrug resistance and cancer: the role of the human ABC transporter ABCG2.
Ejendal KF; Hrycyna CA
Curr Protein Pept Sci; 2002 Oct; 3(5):503-11. PubMed ID: 12369998
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of ATP-binding cassette transporter ABCG2 as a potential mechanism of acquired resistance to vemurafenib in BRAF(V600E) mutant cancer cells.
Wu CP; Sim HM; Huang YH; Liu YC; Hsiao SH; Cheng HW; Li YQ; Ambudkar SV; Hsu SC
Biochem Pharmacol; 2013 Feb; 85(3):325-34. PubMed ID: 23153455
[TBL] [Abstract][Full Text] [Related]
18. Genotyping of the ABCG2 gene using Matrix-Associated Laser Desorption/Ionisation, Time-of-Flight Mass Spectrometry.
Tanaka M; Kamada I; Takahashi J; Kimura T; Tani Y
Transfus Med; 2018 Jun; 28(3):255-260. PubMed ID: 28940904
[TBL] [Abstract][Full Text] [Related]
19. A novel ABCG2 variant causing Jr(a-) phenotype.
Kwon SS; Yun YE; Kim NH; Suh EJ; Kim SK; Kim S
Transfusion; 2024 Apr; 64(4):E9-E10. PubMed ID: 38361420
[No Abstract] [Full Text] [Related]
20. No association between MTHFR C677T and serum uric acid levels among Japanese with ABCG2 126QQ and SLC22A12 258WW.
Hinohara Y; Naito M; Okada R; Yin G; Higashibata T; Tamura T; Kawai S; Morita E; Wakai K; Matsuo H; Mori A; Hamajima N
Nagoya J Med Sci; 2013 Feb; 75(1-2):93-100. PubMed ID: 23544272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
